25,142 XNAS Volume
XNAS 28 Mar, 2025 10:24 AM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Gregory G. Freitag | Director | Purchase of securities on an exchange or from another person at price $ 1.66 per share. | 28 Feb 2025 | 15,060 | 61,213 (0%) | 0% | 1.7 | 25,000 | Common Stock |
| Gregory G. Freitag | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 28 Feb 2025 | 15,060 | 15,060 | - | - | Common Warrant | |
| Richard Brook Sykes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 9,000 | 9,000 | - | - | Employee Stock Option (Right to Buy) | |
| Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 9,000 | 9,000 | - | - | Employee Stock Option (Right to Buy) | |
| Gregory G. Freitag | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 9,000 | 9,000 | - | - | Employee Stock Option (Right to Buy) | |
| Kamil Ali-Jackson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 9,000 | 9,000 | - | - | Employee Stock Option (Right to Buy) | |
| Ilian Petkov Iliev | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 9,000 | 9,000 | - | - | Employee Stock Option (Right to Buy) | |
| Stephan F. Toutain | Chief Operations Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 200,000 | 200,000 | - | - | Employee Stock Option (Right to Buy) | |
| V. Shepard Kirk | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2024 | 200,000 | 200,000 | - | - | Employee Stock Option (Right to Buy) | |
| Boesgaard Lars | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Dec 2023 | 200,000 | 200,000 | - | - | Employee Stock Option (Right to Buy) | |
| Richard Brook Sykes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2023 | 9,000 | 9,000 | - | - | Employee Stock Option (Right to Buy) | |
| Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2023 | 9,000 | 9,000 | - | - | Employee Stock Option (Right to Buy) | |
| Gregory G. Freitag | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2023 | 9,000 | 9,000 | - | - | Employee Stock Option (Right to Buy) | |
| Kamil Ali-Jackson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2023 | 9,000 | 9,000 | - | - | Employee Stock Option (Right to Buy) | |
| Ilian Petkov Iliev | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2023 | 9,000 | 9,000 | - | - | Employee Stock Option (Right to Buy) | |
| Frank Bedu-Addo | Director, President/CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 385,300 | 385,300 | - | - | Employee Stock Option (Right to Buy) | |
| Gregory L. Conn | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 137,200 | 137,200 | - | - | Employee Stock Option (Right to Buy) | |
| Lauren Wood | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 110,800 | 110,800 | - | - | Employee Stock Option (Right to Buy) | |
| Spencer D. Brown | Senior VP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 20,400 | 20,400 | - | - | Employee Stock Option (Right to Buy) | |
| Frank Bedu-Addo | Director, President/CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.57 per share. | 02 Dec 2022 | 219,535 | 866,050 (5%) | 1% | 6.6 | 1,442,345 | Common Stock |
| Frank Bedu-Addo | Director, President/CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2022 | 219,535 | 0 | - | - | Stock Option (Right to Buy) | |
| Frank Bedu-Addo | Director, President/CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.78 per share. | 02 Dec 2022 | 175,184 | 690,866 (4%) | 1% | 9.8 | 1,713,300 | Common Stock |
| Richard Brook Sykes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2022 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2022 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Gregory G. Freitag | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2022 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Kamil Ali-Jackson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2022 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Ilian Petkov Iliev | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2022 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Spencer D. Brown | Senior VP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 150,000 | 150,000 | - | - | Employee Stock Option (Right to Buy) | |
| Frank Bedu-Addo | Director, President/CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2022 | 291,500 | 291,500 | - | - | Stock Option (Right to Buy) | |
| Gregory L. Conn | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2022 | 112,100 | 112,100 | - | - | Employee Stock Option (Right to Buy) | |
| Lauren Wood | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2022 | 88,600 | 88,600 | - | - | Employee Stock Option (Right to Buy) | |
| Richard Brook Sykes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Ilian Petkov Iliev | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Gregory G. Freitag | Director | Purchase of securities on an exchange or from another person at price $ 8.50 per share. | 15 Jun 2021 | 5,882 | 46,153 (0%) | 0% | 8.5 | 49,997 | Common Stock |
| Gregory G. Freitag | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Kamil Ali-Jackson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Kamil Ali-Jackson | Director | Purchase of securities on an exchange or from another person at price $ 8.50 per share. | 15 Jun 2021 | 11,764 | 11,764 (0%) | 0% | 8.5 | 99,994 | Common Stock |
| Frank Bedu-Addo | Director, President/CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.57 per share. | 15 Jun 2021 | 53,174 | 673,681 (4%) | 0% | 6.6 | 349,353 | Common Stock |
| Frank Bedu-Addo | Director, President/CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.86 per share. | 15 Jun 2021 | 27,166 | 646,515 (4%) | 0% | 12.9 | 349,355 | Common Stock |
| Frank Bedu-Addo | Director, President/CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2021 | 53,174 | 0 | - | - | Stock Option (Right to Buy) | |
| Otis W. Brawley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Nov 2020 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Richard Brook Sykes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2020 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Gregory G. Freitag | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2020 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Kamil Ali-Jackson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2020 | 3,033 | 3,033 | - | - | Stock Option (Right to Buy) | |
| Frank Bedu-Addo | Director, President/CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2020 | 125,000 | 125,000 | - | - | Employee Stock Option (Right to Buy) | |
| Gregory L. Conn | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2020 | 35,000 | 35,000 | - | - | Employee Stock Option (Right to Buy) | |
| Lauren Wood | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2020 | 35,000 | 35,000 | - | - | Employee Stock Option (Right to Buy) | |
| Ilian Petkov Iliev | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2020 | 1,874 | 1,874 | - | - | Stock Option (Right to Buy) | |
| Ilian Petkov Iliev | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2020 | 4,500 | 4,500 | - | - | Stock Option (Right to Buy) | |
| Kamil Ali-Jackson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2020 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Richard Brook Sykes | Director | Grant, award, or other acquisition of securities at price $ 1.30 per share. | 14 Feb 2020 | 384,615 | 445,108 (3%) | 2% | 1.3 | 500,000 | Common Stock |
| Gregory G. Freitag | Director | Grant, award, or other acquisition of securities at price $ 1.30 per share. | 14 Feb 2020 | 38,400 | 40,271 (0%) | 0% | 1.3 | 49,920 | Common Stock |
| Andrew Saik | Director, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 1.30 per share. | 14 Feb 2020 | 38,400 | 42,549 (0%) | 0% | 1.3 | 49,920 | Common Stock |
| James J. Loughlin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2019 | 9,000 | 9,000 | - | - | Stock Option (Right To Purchase) | |
| Richard Sykes | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2019 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Gregory G. Freitag | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2019 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Frank Bedu-Addo | Director, President/CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2019 | 100,000 | 100,000 | - | - | Employee Stock Option (Right to Buy) | |
| Andrew Saik | Director, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2019 | 62,715 | 62,715 | - | - | Stock Option (Right To Purchase) | |
| Gregory L. Conn | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2019 | 40,000 | 40,000 | - | - | Stock Option (Right To Purchase) | |
| Lauren Wood | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2019 | 62,715 | 62,715 | - | - | Stock Option (Right To Purchase) | |
| W. Bradford Middlekauff | Senior VP, GC and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Mar 2019 | 49,766 | 59,766 (0%) | 0% | 0 | Common Stock | |
| W. Bradford Middlekauff | Senior VP, GC and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Mar 2019 | 49,766 | 0 | - | - | Restricted Stock Units | |
| James J. Loughlin | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2019 | 10,000 | 0 | - | - | Restricted Stock Units | |
| James J. Loughlin | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2019 | 10,000 | 26,625 (0%) | 0% | 0 | Common Stock | |
| Sol J. Barer | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2019 | 20,000 | 0 | - | - | Restricted Stock Units | |
| Sol J. Barer | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2019 | 20,000 | 678,075 (4%) | 0% | 0 | Common Stock | |
| Robert J. Spiegel | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2019 | 10,000 | 48,661 (0%) | 0% | 0 | Common Stock | |
| Robert J. Spiegel | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2019 | 10,000 | 0 | - | - | Restricted Stock Units | |
| Rosemary A. Crane | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2019 | 10,000 | 0 | - | - | Restricted Stock Units | |
| Rosemary A. Crane | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2019 | 10,000 | 10,000 (0%) | 0% | 0 | Common Stock | |
| Isaac Blech | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2019 | 10,000 | 0 | - | - | Restricted Stock Units | |
| Isaac Blech | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2019 | 10,000 | 10,000 (0%) | 0% | 0 | Common Stock | |
| Isaac Blech | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2019 | 10,000 | 0 | - | - | Restricted Stock Units | |
| Isaac Blech | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2019 | 10,000 | 10,000 (0%) | 0% | 0 | Common Stock | |
| Liam Ratcliffe | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2019 | 10,000 | 10,000 (0%) | 0% | 0 | Common Stock | |
| Liam Ratcliffe | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2019 | 10,000 | 0 | - | - | Restricted Stock Units | |
| Andrew Saik | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2019 | 82,999 | 0 | - | - | Restricted Stock Units | |
| Andrew Saik | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2019 | 82,999 | 82,999 (0%) | 0% | 0 | Common Stock | |
| Brian A. Leuthner | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2019 | 169,032 | 239,268 (1%) | 0% | 0 | Common Stock | |
| Brian A. Leuthner | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2019 | 169,032 | 0 | - | - | Restricted Stock Units | |
| R. Loch Macdonald | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2019 | 10,000 | 580,602 (4%) | 0% | 0 | Common Stock | |
| R. Loch Macdonald | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2019 | 10,000 | 0 | - | - | Restricted Stock Units | |
| Albert N. Marchio | Chief Accounting & Adm Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2018 | 41,666 | 41,666 | - | - | Restricted Stock Units | |
| James J. Loughlin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2018 | 10,000 | 10,000 | - | - | Restricted Stock Units | |
| Sol J. Barer | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2018 | 20,000 | 20,000 | - | - | Restricted Stock Units | |
| W. Bradford Middlekauff | Senior VP, GC and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2018 | 49,766 | 49,766 | - | - | Restricted Stock Units | |
| Robert J. Spiegel | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2018 | 10,000 | 10,000 | - | - | Restricted Stock Units | |
| Rosemary A. Crane | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2018 | 10,000 | 10,000 | - | - | Restricted Stock Units | |
| Isaac Blech | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2018 | 10,000 | 10,000 | - | - | Restricted Stock Units | |
| Liam Ratcliffe | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2018 | 10,000 | 10,000 | - | - | Restricted Stock Units | |
| Andrew Saik | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2018 | 82,999 | 82,999 | - | - | Restricted Stock Units | |
| Brian A. Leuthner | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2018 | 169,032 | 169,032 | - | - | Restricted Stock Units | |
| R. Loch Macdonald | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2018 | 10,000 | 10,000 | - | - | Restricted Stock Units | |
| Herbert J. Faleck | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2018 | 59,833 | 59,833 | - | - | Restricted Stock Units | |
| Albert N. Marchio | Chief Accounting & Adm Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2018 | 83,334 | 83,334 | - | - | Stock Option (Right To Purchase) | |
| James J. Loughlin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2018 | 20,000 | 20,000 | - | - | Stock Option (Right To Purchase) | |
| Sol J. Barer | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2018 | 40,000 | 40,000 | - | - | Stock Option (Right To Purchase) | |
| W. Bradford Middlekauff | Senior VP, GC and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2018 | 99,534 | 99,534 | - | - | Stock Option (Right To Purchase) | |
| Robert J. Spiegel | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2018 | 20,000 | 20,000 | - | - | Stock Option (Right To Purchase) | |
| Rosemary A. Crane | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2018 | 20,000 | 20,000 | - | - | Stock Option (Right To Purchase) | |
| Isaac Blech | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2018 | 20,000 | 20,000 | - | - | Stock Option (Right To Purchase) | |
| Liam Ratcliffe | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2018 | 20,000 | 20,000 | - | - | Stock Option (Right To Purchase) | |
| Andrew Saik | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2018 | 166,001 | 166,001 | - | - | Stock Option (Right To Purchase) | |
| Brian A. Leuthner | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2018 | 338,068 | 338,068 | - | - | Stock Option (Right To Purchase) | |
| R. Loch Macdonald | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2018 | 20,000 | 20,000 | - | - | Stock Option (Right To Purchase) | |
| Herbert J. Faleck | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2018 | 119,667 | 119,667 | - | - | Stock Option (Right To Purchase) | |
| Alyssa Wyant | SVP Regulatory Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2018 | 99,534 | 99,534 | - | - | Stock Option (Right To Purchase) | |
| Kurt Conti | None | Other type of transaction at price $ 0.00 per share. | 23 Mar 2018 | 58,476 | 0 (0%) | 0% | 0 | Common Stock | |
| R. Loch Macdonald | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 16.41 per share. | 22 Mar 2018 | 2,500 | 570,602 (1%) | 0% | 16.4 | 41,025 | Common Stock |
| R. Loch Macdonald | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 16.47 per share. | 19 Mar 2018 | 5,000 | 575,602 (1%) | 0% | 16.5 | 82,350 | Common Stock |
| R. Loch Macdonald | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 16.52 per share. | 19 Mar 2018 | 2,500 | 573,102 (1%) | 0% | 16.5 | 41,300 | Common Stock |
| R. Loch Macdonald | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 16.66 per share. | 19 Mar 2018 | 2,500 | 580,602 (1%) | 0% | 16.7 | 41,650 | Common Stock |
| Albert N. Marchio | Chief Accounting & Adm Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2018 | 25,000 | 25,000 | - | - | Stock Option (Right To Purchase) | |
| W. Bradford Middlekauff | Senior VP, GC and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2018 | 65,000 | 65,000 | - | - | Stock Option (Right To Purchase) | |
| Andrew Saik | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2018 | 50,000 | 50,000 | - | - | Stock Option (Right To Purchase) | |
| Herbert J. Faleck | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2018 | 90,000 | 90,000 | - | - | Stock Option (Right To Purchase) | |
| Daniel Brennan | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2018 | 90,000 | 90,000 | - | - | Stock Option (Right To Purchase) | |
| Alyssa Wyant | SVP Regulatory Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2018 | 50,000 | 50,000 | - | - | Stock Option (Right To Purchase) | |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 15.47 per share. | 22 Feb 2018 | 2,500 | 77,736 (0%) | 0% | 15.5 | 38,675 | Common Stock |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 15.37 per share. | 22 Feb 2018 | 2,500 | 75,236 (0%) | 0% | 15.4 | 38,425 | Common Stock |
| R. Loch Macdonald | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 14.49 per share. | 20 Feb 2018 | 2,500 | 583,102 (1%) | 0% | 14.5 | 36,225 | Common Stock |
| R. Loch Macdonald | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 13.75 per share. | 20 Feb 2018 | 5,000 | 590,602 (1%) | 0% | 13.8 | 68,750 | Common Stock |
| R. Loch Macdonald | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 13.82 per share. | 20 Feb 2018 | 5,000 | 585,602 (1%) | 0% | 13.8 | 69,100 | Common Stock |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 12.96 per share. | 01 Feb 2018 | 2,500 | 80,236 (0%) | 0% | 13.0 | 32,400 | Common Stock |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 13.14 per share. | 01 Feb 2018 | 2,500 | 82,736 (0%) | 0% | 13.1 | 32,850 | Common Stock |
| Albert N. Marchio | Chief Accounting & Adm Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2018 | 50,000 | 50,000 | - | - | Stock Option (Right To Purchase) | |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.11 per share. | 02 Jan 2018 | 2,500 | 85,236 (0%) | 0% | 10.1 | 25,275 | Common Stock |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.11 per share. | 02 Jan 2018 | 2,500 | 87,736 (0%) | 0% | 10.1 | 25,275 | Common Stock |
| Herbert J. Faleck | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2018 | 50,000 | 50,000 | - | - | Stock Option (Right To Purchase) | |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.97 per share. | 01 Dec 2017 | 2,500 | 92,736 (0%) | 0% | 10.0 | 24,925 | Common Stock |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.68 per share. | 01 Dec 2017 | 2,500 | 90,236 (0%) | 0% | 9.7 | 24,200 | Common Stock |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.92 per share. | 01 Dec 2017 | 2,500 | 95,236 (0%) | 0% | 9.9 | 24,800 | Common Stock |
| Andrew Saik | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2017 | 200,000 | 200,000 | - | - | Stock Option (Right To Purchase) | |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.92 per share. | 01 Nov 2017 | 2,500 | 102,736 (0%) | 0% | 10.9 | 27,300 | Common Stock |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.86 per share. | 01 Nov 2017 | 2,500 | 97,736 (0%) | 0% | 10.9 | 27,150 | Common Stock |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.94 per share. | 01 Nov 2017 | 2,500 | 100,236 (0%) | 0% | 10.9 | 27,350 | Common Stock |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.93 per share. | 02 Oct 2017 | 2,500 | 107,736 (0%) | 0% | 10.9 | 27,325 | Common Stock |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 11.14 per share. | 02 Oct 2017 | 2,500 | 105,236 (0%) | 0% | 11.1 | 27,850 | Common Stock |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.81 per share. | 02 Oct 2017 | 2,500 | 110,236 (0%) | 0% | 10.8 | 27,025 | Common Stock |
| Rosemary A. Crane | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Sep 2017 | 30,000 | 30,000 | - | - | Stock Option (Right To Purchase) | |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.94 per share. | 01 Sep 2017 | 2,500 | 115,236 (0%) | 0% | 9.9 | 24,850 | Common Stock |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.37 per share. | 01 Sep 2017 | 2,500 | 117,736 (0%) | 0% | 10.4 | 25,925 | Common Stock |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.31 per share. | 01 Sep 2017 | 2,500 | 112,736 (0%) | 0% | 10.3 | 25,775 | Common Stock |
| Albert N. Marchio | Chief Accounting & Adm Officer | Sale of securities on an exchange or to another person at price $ 10.42 per share. | 29 Aug 2017 | 2,500 | 3,361 (0%) | 0% | 10.4 | 26,050 | Common Stock |
| Albert N. Marchio | Chief Accounting & Adm Officer | Sale of securities on an exchange or to another person at price $ 10.39 per share. | 23 Aug 2017 | 1,000 | 5,861 (0%) | 0% | 10.4 | 10,390 | Common Stock |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.65 per share. | 01 Aug 2017 | 2,500 | 125,236 (0%) | 0% | 10.7 | 26,625 | Common Stock |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.53 per share. | 01 Aug 2017 | 2,500 | 122,736 (0%) | 0% | 10.5 | 26,325 | Common Stock |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.40 per share. | 01 Aug 2017 | 2,500 | 120,236 (0%) | 0% | 10.4 | 26,000 | Common Stock |
| Sol J. Barer | None | 07 Jul 2017 | 12,530 | 0 | - | - | Warrants (right To Purchase) | ||
| Sol J. Barer | None | 07 Jul 2017 | 12,530 | 658,075 (2%) | 0% | 2.4 | 29,947 | Common Stock | |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.21 per share. | 03 Jul 2017 | 2,500 | 130,236 (0%) | 0% | 10.2 | 25,525 | Common Stock |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.08 per share. | 03 Jul 2017 | 2,500 | 127,736 (0%) | 0% | 10.1 | 25,200 | Common Stock |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.27 per share. | 03 Jul 2017 | 2,500 | 132,736 (0%) | 0% | 10.3 | 25,675 | Common Stock |
| James J. Loughlin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2017 | 15,000 | 15,000 | - | - | Stock Option (right To Purchase) | |
| Sol J. Barer | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2017 | 30,000 | 30,000 | - | - | Stock Option (right To Purchase) | |
| James I. Healy | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2017 | 15,000 | 15,000 | - | - | Stock Option (right To Purchase) | |
| Robert J. Spiegel | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2017 | 15,000 | 15,000 | - | - | Stock Option (right To Purchase) | |
| Isaac Blech | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2017 | 15,000 | 15,000 | - | - | Stock Option (right To Purchase) | |
| Liam Ratcliffe | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2017 | 15,000 | 15,000 | - | - | Stock Option (right To Purchase) | |
| Kurt Conti | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2017 | 15,000 | 15,000 | - | - | Stock Option (right To Purchase) | |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 11.10 per share. | 26 Apr 2017 | 100 | 135,236 (0%) | 0% | 11.1 | 1,110 | Common Stock |
| Albert N. Marchio | Chief Accounting & Ops Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2017 | 47,500 | 47,500 | - | - | Stock Option (right To Purchase) | |
| W. Bradford Middlekauff | Senior VP, GC and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2017 | 52,500 | 52,500 | - | - | Stock Option (right To Purchase) | |
| Brian A. Leuthner | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2017 | 267,500 | 267,500 | - | - | Stock Option (right To Purchase) | |
| R. Loch Macdonald | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2017 | 110,000 | 110,000 | - | - | Stock Option (right To Purchase) | |
| Herbert J. Faleck | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2017 | 110,000 | 110,000 | - | - | Stock Option (right To Purchase) | |
| Alpaslan Yaman | V.P., Technical Ops. & Mfg. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2017 | 40,000 | 40,000 | - | - | Stock Option (right To Purchase) | |
| James J. Loughlin | None | Purchase of securities on an exchange or from another person at price $ 9.24 per share. | 06 Mar 2017 | 3,000 | 6,000 (0%) | 0% | 9.2 | 27,720 | Common Stock |
| Andrew J. Einhorn | Chief Financial Officer | 01 Mar 2017 | 1,567 | 43,223 (0%) | 0% | 2.4 | 3,745 | Common Stock | |
| Andrew J. Einhorn | Chief Financial Officer | 01 Mar 2017 | 1,567 | 0 | - | - | Warrants (right To Purchase) | ||
| Alyssa Wyant | SVP Regulatory Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2017 | 80,000 | 80,000 | - | - | Stock Option (right To Purchase) | |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.52 per share. | 07 Feb 2017 | 1,500 | 245,479 (0%) | 0% | 9.5 | 14,280 | Common Stock |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.69 per share. | 03 Feb 2017 | 1,500 | 248,479 (0%) | 0% | 9.7 | 14,535 | Common Stock |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.52 per share. | 03 Feb 2017 | 1,500 | 246,979 (0%) | 0% | 9.5 | 14,280 | Common Stock |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.38 per share. | 01 Feb 2017 | 1,500 | 251,479 (0%) | 0% | 9.4 | 14,070 | Common Stock |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.61 per share. | 01 Feb 2017 | 1,500 | 249,979 (0%) | 0% | 9.6 | 14,415 | Common Stock |
| R. Loch Macdonald | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.04 per share. | 23 Jan 2017 | 25,000 | 595,602 (2%) | 0% | 2.0 | 51,000 | Common Stock |
| R. Loch Macdonald | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2017 | 25,000 | 75,504 | - | - | Stock Option (right To Purchase) | |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 01 Dec 2016 | 7,500 | 252,979 | - | - | Common Stock | |
| Daniel Brennan | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2016 | 150,000 | 150,000 | - | - | Stock Option (right To Purchase) | |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 03 Oct 2016 | 7,500 | 260,479 | - | - | Common Stock | |
| W. Bradford Middlekauff | Senior VP, GC and Secretary | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 05 Aug 2016 | 143 | 10,000 | - | - | Common Stock | |
| W. Bradford Middlekauff | Senior VP, GC and Secretary | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 05 Aug 2016 | 9,857 | 9,857 | - | - | Common Stock | |
| Brian A. Leuthner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 01 Aug 2016 | 7,500 | 267,979 | - | - | Common Stock | |
| Sol J. Barer | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2016 | 30,000 | 30,000 | - | - | Stock Option (right To Purchase) | |
| James I. Healy | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2016 | 15,000 | 15,000 | - | - | Stock Option (right To Purchase) | |
| James J. Loughlin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2016 | 15,000 | 15,000 | - | - | Stock Option (right To Purchase) | |
| Robert J. Spiegel | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2016 | 15,000 | 15,000 | - | - | Stock Option (right To Purchase) | |
| Isaac Blech | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2016 | 15,000 | 15,000 | - | - | Stock Option (right To Purchase) | |
| Liam Ratcliffe | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2016 | 30,000 | 30,000 | - | - | Stock Option (right to purchase) | |
| Kurt Conti | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2016 | 15,000 | 15,000 | - | - | Stock Option (right To Purchase) | |
| Renu Vaish | V.P., Global Reg. Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2016 | 5,000 | 115,605 | - | - | Stock Option (right To Purchase) | |
| Renu Vaish | V.P., Global Reg. Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2016 | 5,000 | 5,350 | - | - | Common Stock | |
| James I. Healy | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 11 Mar 2016 | 541,343 | 2,852,711 | - | - | Common Stock | |
| James J. Loughlin | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 11 Mar 2016 | 1,107 | 1,720 | - | - | Common Stock | |
| James J. Loughlin | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 11 Mar 2016 | 500 | 613 | - | - | Common Stock | |
| James J. Loughlin | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 11 Mar 2016 | 180 | 3,000 | - | - | Common Stock | |
| James J. Loughlin | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 11 Mar 2016 | 13 | 113 | - | - | Common Stock | |
| James J. Loughlin | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 11 Mar 2016 | 500 | 2,820 | - | - | Common Stock | |
| James J. Loughlin | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 11 Mar 2016 | 100 | 100 | - | - | Common Stock | |
| James J. Loughlin | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 11 Mar 2016 | 600 | 2,320 | - | - | Common Stock | |
| Herbert J. Faleck | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2016 | 25,000 | 25,000 | - | - | Stock Option (right To Purchase) | |
| W. Bradford Middlekauff | Senior VP, GC and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2016 | 35,000 | 35,000 | - | - | Stock Option (Right to Purchase) | |
| Andrew J. Einhorn | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2016 | 50,000 | 50,000 | - | - | Stock Option (Right to Purchase) | |
| Brian A. Leuthner | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2016 | 230,000 | 230,000 | - | - | Stock Option (Right to Purchase) | |
| Albert N. Marchio | Chief Accounting & Ops Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2016 | 35,000 | 35,000 | - | - | Stock Option (Right to Purchase) | |
| Herbert J. Faleck | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2016 | 110,000 | 110,000 | - | - | Stock Option (Right to Purchase) | |
| Renu Vaish | V.P., Global Reg. Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2016 | 30,500 | 30,500 | - | - | Stock Option (Right to Purchase) | |
| Alpaslan Yaman | V.P., Technical Ops. & Mfg. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2016 | 35,000 | 35,000 | - | - | Stock Option (Right to Purchase) | |
| W. Bradford Middlekauff | Senior VP, GC and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2015 | 80,000 | 80,000 | - | - | Stock Option (Right to Purchase) | |
| Sol J. Barer | None | 06 Oct 2015 | 480,000 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Sol J. Barer | None | 06 Oct 2015 | 114,285 | 0 | - | - | Series B-1 Convertible Preferred Stock | ||
| Sol J. Barer | None | 06 Oct 2015 | 65,809 | 0 | - | - | Series C Convertible Preferred Stock | ||
| Sol J. Barer | None | 06 Oct 2015 | 144,086 | 0 | - | - | Series C-2 Convertible Preferred Stock | ||
| Sol J. Barer | None | 06 Oct 2015 | 350,852 | 350,852 | - | - | Common Stock | ||
| Sol J. Barer | None | 06 Oct 2015 | 83,536 | 434,388 | - | - | Common Stock | ||
| Sol J. Barer | None | 06 Oct 2015 | 48,103 | 482,491 | - | - | Common Stock | ||
| Sol J. Barer | None | 06 Oct 2015 | 105,319 | 587,810 | - | - | Common Stock | ||
| Sol J. Barer | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 06 Oct 2015 | 45,000 | 632,810 | - | - | Common Stock | |
| Sol J. Barer | None | Other type of transaction at price $ 0.00 per share. | 06 Oct 2015 | 12,735 | 645,545 | - | - | Common Stock | |
| James I. Healy | None | 06 Oct 2015 | 2,473,118 | 0 | - | - | Series C-2 Convertible Preferred Stock | ||
| James I. Healy | None | 06 Oct 2015 | 1,807,703 | 1,807,703 | - | - | Common Stock | ||
| James I. Healy | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 06 Oct 2015 | 450,000 | 2,257,703 | - | - | Common Stock | |
| James I. Healy | None | Other type of transaction at price $ 0.00 per share. | 06 Oct 2015 | 53,665 | 2,311,368 | - | - | Common Stock | |
| James J. Loughlin | None | 06 Oct 2015 | 16,774 | 0 | - | - | Series C-2 Convertible Preferred Stock | ||
| James J. Loughlin | None | 06 Oct 2015 | 12,261 | 12,261 | - | - | Common Stock | ||
| James J. Loughlin | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 06 Oct 2015 | 7,000 | 19,261 | - | - | Common Stock | |
| James J. Loughlin | None | Other type of transaction at price $ 0.00 per share. | 06 Oct 2015 | 364 | 19,625 | - | - | Common Stock | |
| Anders D. Hove | None | 06 Oct 2015 | 2,150,538 | 0 | - | - | Series C-2 Convertible Preferred Stock | ||
| Anders D. Hove | None | 06 Oct 2015 | 1,571,917 | 1,571,917 | - | - | Common Stock | ||
| Anders D. Hove | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 06 Oct 2015 | 450,000 | 2,021,917 | - | - | Common Stock | |
| Anders D. Hove | None | Other type of transaction at price $ 0.00 per share. | 06 Oct 2015 | 46,665 | 2,068,582 | - | - | Common Stock | |
| Robert J. Spiegel | None | 06 Oct 2015 | 32,258 | 0 | - | - | Series C-1 Convertible Preferred Stock | ||
| Robert J. Spiegel | None | 06 Oct 2015 | 14,409 | 0 | - | - | Series C-2 Convertible Preferred Stock | ||
| Robert J. Spiegel | None | 06 Oct 2015 | 23,579 | 23,579 | - | - | Common Stock | ||
| Robert J. Spiegel | None | 06 Oct 2015 | 10,533 | 34,112 | - | - | Common Stock | ||
| Robert J. Spiegel | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 06 Oct 2015 | 3,000 | 37,112 | - | - | Common Stock | |
| Robert J. Spiegel | None | Other type of transaction at price $ 0.00 per share. | 06 Oct 2015 | 1,549 | 38,661 | - | - | Common Stock | |
| Andrew J. Einhorn | Chief Financial Officer | 06 Oct 2015 | 14,286 | 0 | - | - | Series B-1 Convertible Preferred Stock | ||
| Andrew J. Einhorn | Chief Financial Officer | 06 Oct 2015 | 6,494 | 0 | - | - | Series C Convertible Preferred Stock | ||
| Andrew J. Einhorn | Chief Financial Officer | 06 Oct 2015 | 32,956 | 0 | - | - | Series C-1 Convertible Preferred Stock | ||
| Andrew J. Einhorn | Chief Financial Officer | 06 Oct 2015 | 21,506 | 0 | - | - | Series C-1 Convertible Preferred Stock | ||
| Andrew J. Einhorn | Chief Financial Officer | 06 Oct 2015 | 29,032 | 0 | - | - | Series C-2 Convertible Preferred Stock | ||
| Andrew J. Einhorn | Chief Financial Officer | 06 Oct 2015 | 10,443 | 10,443 | - | - | Common Stock | ||
| Andrew J. Einhorn | Chief Financial Officer | 06 Oct 2015 | 4,747 | 15,190 | - | - | Common Stock | ||
| Andrew J. Einhorn | Chief Financial Officer | 06 Oct 2015 | 24,089 | 39,279 | - | - | Common Stock | ||
| Andrew J. Einhorn | Chief Financial Officer | Other type of transaction at price $ 0.00 per share. | 06 Oct 2015 | 2,377 | 41,656 | - | - | Common Stock | |
| Andrew J. Einhorn | Chief Financial Officer | 06 Oct 2015 | 15,720 | 15,720 | - | - | Common Stock | ||
| Andrew J. Einhorn | Chief Financial Officer | 06 Oct 2015 | 21,221 | 36,941 | - | - | Common Stock | ||
| Andrew J. Einhorn | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 06 Oct 2015 | 45,000 | 81,941 | - | - | Common Stock | |
| Andrew J. Einhorn | Chief Financial Officer | Other type of transaction at price $ 0.00 per share. | 06 Oct 2015 | 1,651 | 83,592 | - | - | Common Stock | |
| Brian A. Leuthner | Director, Chief Executive Officer | 06 Oct 2015 | 3,655 | 0 | - | - | Series C-2 Convertible Preferred Stock | ||
| Brian A. Leuthner | Director, Chief Executive Officer | 06 Oct 2015 | 2,672 | 550,878 | - | - | Common Stock | ||
| Brian A. Leuthner | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 06 Oct 2015 | 80 | 550,958 | - | - | Common Stock | |
| R. Loch Macdonald | Director, Chief Scientific Officer | 06 Oct 2015 | 25,000 | 0 | - | - | Series A Convertible Preferred Stock | ||
| R. Loch Macdonald | Director, Chief Scientific Officer | 06 Oct 2015 | 5,373 | 0 | - | - | Series C-1 Convertible Preferred Stock | ||
| R. Loch Macdonald | Director, Chief Scientific Officer | 06 Oct 2015 | 18,274 | 566,480 | - | - | Common Stock | ||
| R. Loch Macdonald | Director, Chief Scientific Officer | 06 Oct 2015 | 3,928 | 570,408 | - | - | Common Stock | ||
| R. Loch Macdonald | Director, Chief Scientific Officer | Other type of transaction at price $ 0.00 per share. | 06 Oct 2015 | 194 | 570,602 | - | - | Common Stock | |
| Albert N. Marchio | Chief Acct. & Op., Asst. Sec. | 06 Oct 2015 | 7,530 | 0 | - | - | Series C-1 Convertible Preferred Stock | ||
| Albert N. Marchio | Chief Acct. & Op., Asst. Sec. | 06 Oct 2015 | 5,504 | 5,504 | - | - | Common Stock | ||
| Albert N. Marchio | Chief Acct. & Op., Asst. Sec. | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 06 Oct 2015 | 100 | 6,504 | - | - | Common Stock | |
| Albert N. Marchio | Chief Acct. & Op., Asst. Sec. | Other type of transaction at price $ 0.00 per share. | 06 Oct 2015 | 357 | 6,861 | - | - | Common Stock | |
| Herbert J. Faleck | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 06 Oct 2015 | 500 | 500 | - | - | Common Stock | |
| Kurt Conti | None | 06 Oct 2015 | 220,000 | 0 | - | - | Series A Convertible Preferred Stock | ||
| Kurt Conti | None | 06 Oct 2015 | 224,000 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Kurt Conti | None | 06 Oct 2015 | 40,000 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Kurt Conti | None | 06 Oct 2015 | 20,000 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Kurt Conti | None | 06 Oct 2015 | 20,000 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Kurt Conti | None | 06 Oct 2015 | 1,080,000 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Kurt Conti | None | 06 Oct 2015 | 160,810 | 160,810 | - | - | Common Stock | ||
| Kurt Conti | None | 06 Oct 2015 | 163,731 | 324,541 | - | - | Common Stock | ||
| Kurt Conti | None | 06 Oct 2015 | 29,238 | 29,238 | - | - | Common Stock | ||
| Kurt Conti | None | 06 Oct 2015 | 14,619 | 14,619 | - | - | Common Stock | ||
| Kurt Conti | None | 06 Oct 2015 | 14,619 | 14,619 | - | - | Common Stock | ||
| Kurt Conti | None | 06 Oct 2015 | 789,420 | 789,420 | - | - | Common Stock | ||
| Renu Vaish | V.P., Global Reg. Affairs | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 06 Oct 2015 | 350 | 350 | - | - | Common Stock |